DC Chemicals Limited
China
Product Name: KP1019(FFC14A)
Price: $1800.0/1g $2800.0/3g $3900.0/5g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

124875-20-3

124875-20-3 structure

124875-20-3 structure

Name: KP1019(FFC14A)
Chemical Name: trans-RuCl4(1H-indazole)2
CAS Number: 124875-20-3
Molecular Formula: C₂₁H₁₈Cl₄N₆Ru
Molecular Weight: 598.29800
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2017-12-27 20:05:02
Modify Date: 2024-01-02 19:37:44
KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells[1][2].

Name	trans-RuCl4(1H-indazole)2
Synonyms	indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] KP 1019 indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] indazolium trans-[tetrachlorobisindazole ruthenate(III)] KP1019

Description	KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	KP1019 is internalized by yeast and induces mutations, cell cycle delay, and cell death. KP1019 sensitivity of strains defective in DNA repair is examined, ultimately showing that rad1Δ, rev3Δ, and rad52Δ yeast are hypersensitive to KP1019, suggesting that nucleotide excision repair (NER), translesion synthesis (TLS), and recombination each play a role in drug tolerance[1]. KP1019 inhibits proliferation of ovarian tumor cells, induces DNA damage and apoptosis in colon carcinoma cells. KP1019 causes interstrand cross-links and bulky DNA adducts in mammalian cell lines[1].
In Vivo	KP1019 treatment inhibits primary tumour growth in in the model of MCa mammary carcinoma. None of the treatments reduced the development of lung metastatases in this tumour model[3]. Animal Model: CBA female mice bearing murine mammary carcinoma[3] Dosage: 40 mg/kg and 80 mg/kg Administration: I.P.; two dose levels of 40 mg/kg from day 6 to day 11, and 80 mg/kg on days 7, 9, and 11 Result: Inhibited primary tumour growth.
References	[1]. Shannon K Stevens, et al. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae. Mol Pharmacol. 2013 Jan;83(1):225-34. [2]. Gemma K Gransbury, et al. Comparison of KP1019 and NAMI-A in tumour-mimetic environments. Metallomics. 2016 Aug 1;8(8):762-73. [3]. A Bergamo, et al. Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion. Met Based Drugs. 2009;2009:681270.

Molecular Formula	C₂₁H₁₈Cl₄N₆Ru
Molecular Weight	598.29800
Exact Mass	596.94700
PSA	70.12000
LogP	7.44670